阅读说明：本技术 双氢青蒿素在制备治疗硬皮病的药物中的用途 (Application of dihydroartemisinin in preparation of medicine for treating scleroderma ) 是由 严青然 李�瑞 吕良敬 殷瀚林 于 2020-09-03 设计创作，主要内容包括：本发明提供了双氢青蒿素在制备治疗硬皮病的药物中的用途。通过实验证明,全身应用双氢青蒿素(Dihydroartemisinin)可以减少真皮胶原聚集,减轻皮肤纤维化,有效治疗硬皮病。(The invention provides application of dihydroartemisinin in preparation of a medicine for treating scleroderma. Experiments prove that the systemic application of Dihydroartemisinin (dihydroartemesinin) can reduce dermal collagen aggregation, relieve skin fibrosis and effectively treat scleroderma.)

1. Use of dihydroartemisinin for the preparation of a medicament for the treatment of scleroderma.

Technical Field

The invention belongs to the field of biomedicine, and relates to a medicine for treating scleroderma, in particular to application of dihydroartemisinin in preparing a medicine for treating scleroderma.

Background

Scleroderma is a group of autoimmune diseases characterized by local or diffuse fibrosis of the skin, some types of which can be combined with fibrosis of multiple organs, resulting in death of patients, and the origin of the disease is not clear. Of these, focal type is commonly referred to as hard spotting, and systemic type is generally referred to as systemic sclerosis. Fibrosis is a clinical problem, and an effective treatment means is not available at present. Dihydroartemisinin is a derivative of artemisinin, which has the advantages of high efficacy, extremely low toxicity, etc. compared with artemisinin, and was initially studied and applied widely worldwide because of its potent antimalarial effect. Now, the research finds that the dihydroartemisinin also has the functions of participating in oxidative stress of cells, DNA damage repair, mitochondrial homeostasis, immune regulation and the like, has the effectiveness of treating systemic lupus erythematosus, which is an immune disease, and is currently in clinical research. Although scleroderma is also an immune-related disease, there is no report that dihydroartemisinin could exert a therapeutic effect on scleroderma.

Disclosure of Invention

The invention aims to provide application of dihydroartemisinin in preparation of a medicine for treating scleroderma, and the application aims to solve the technical problem that the medicine in the prior art has poor effect on treating scleroderma.

The invention provides application of dihydroartemisinin in preparation of a medicine for treating scleroderma.

Compared with the prior art, the invention has the advantages of positive and obvious technical effect. Experiments prove that the systemic application of Dihydroartemisinin (dihydroartemesinin) can reduce dermal collagen aggregation, relieve skin fibrosis and effectively treat scleroderma.

Drawings

FIG. 1: shows that systemic administration of dihydroartemisinin can effectively alleviate bleomycin-induced skin fibrosis.

FIG. 2: dihydroartemisinin was shown to significantly inhibit transcription of collagen-related genes (a-SMA, fibrinectin, Col1a 1) and to decrease collagen production (collagen 1) time and concentration dependently.

FIG. 3: it is shown that after the Dihydroartemisinin (DHA) treatment for 12h, the red fluorescence spots in the cells are increased compared with the control group, which indicates that the fibroblast autophagy flow induced by the dihydroartemisinin is smooth.

FIG. 4: panel a shows rapamycin induced autophagy with reduced collagen production, indicating that induced autophagy may exert an anti-fibrotic effect; a1 inhibits autophagy, the antifibrotic effect of dihydroartemisinin is partially rescued.

Detailed Description

The experiments described in the examples below used Dihydroartemisinin (Dihydroartemisinin) as a commercial product under the catalog number HY-N0176, available from MCE (MedChemExpress) Inc. of the United states. The mrFP-GFP-LC3 fluorescently-labeled adenovirus used was purchased from Hemanson Biotechnology Ltd. Rapamycin (AY-22989) and Baf.A1 (HY-100558) were used as purchased from MCE (MedChemexpress) Inc. in the United states.